{
  "kind": "treatment",
  "slug": "methylphenidate-er-concerta",
  "type": "stimulant",
  "name": "Methylphenidate ER (Concerta)",
  "summary": "An extended-release formulation of methylphenidate used for attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults.",
  "description": "Methylphenidate ER (Concerta) is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons. It is indicated for the treatment of ADHD and functions through a controlled release mechanism providing therapeutic effects for up to 12 hours. The OROS® osmotic release system delivers an initial dose rapidly, followed by gradual release over the day.",
  "category": "medications/stimulants",
  "tags": [
    "adhd",
    "stimulant",
    "extended-release",
    "dopamine",
    "norepinephrine"
  ],
  "metadata": {
    "drug_classes": [
      "CNS Stimulant"
    ],
    "therapeutic_categories": [
      "ADHD"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Concerta"
    ],
    "dea_schedule": "Schedule II (US)",
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Pediatric",
      "Adolescent",
      "Adult"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Pediatrics"
    ],
    "fda_approval_year": 2000
  },
  "clinical_metadata": {
    "primary_indications": [
      "ADHD"
    ],
    "off_label_uses": [
      "Narcolepsy",
      "Treatment-resistant depression (augmentation)"
    ],
    "contraindications": [
      "Marked anxiety, tension, and agitation",
      "Glaucoma",
      "Tics or family history of Tourette's syndrome",
      "MAOI use within 14 days",
      "Hypersensitivity to methylphenidate"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Growth in children",
      "Signs of misuse or diversion"
    ],
    "efficacy_rating": {
      "ADHD": 5
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "methylphenidate ER",
      "Concerta",
      "stimulant",
      "ADHD",
      "dopamine",
      "norepinephrine"
    ],
    "synonyms": [
      "methylphenidate hydrochloride ER",
      "osmotic-release methylphenidate"
    ],
    "common_misspellings": [
      "methyphenidate",
      "concerta"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)",
        "Narcolepsy (off-label)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks norepinephrine and dopamine reuptake into presynaptic neurons, increasing their availability in the synaptic cleft; uses osmotic-release oral system for extended duration."
    },
    {
      "type": "dosing",
      "adult": {
        "adhd": "18–72 mg once daily in the morning"
      },
      "pediatric": "Start 18 mg once daily; may increase by 18 mg increments at weekly intervals; max 72 mg/day",
      "hepatic_impairment": "No specific adjustment; use with caution",
      "renal_impairment": "No specific adjustment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release tablets: 18 mg, 27 mg, 36 mg, 54 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset: within 30–60 minutes; duration: up to 12 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "insomnia",
        "decreased appetite",
        "dry mouth",
        "increased heart rate",
        "anxiety",
        "headache"
      ],
      "less_common": [
        "abdominal pain",
        "sweating",
        "dizziness"
      ],
      "serious": [
        "sudden cardiac death in patients with structural heart abnormalities",
        "psychosis or mania",
        "seizures",
        "priapism"
      ]
    },
    {
      "type": "warnings",
      "black_box": "High potential for abuse and dependence.",
      "other": [
        "May increase blood pressure and heart rate—monitor regularly",
        "Risk of exacerbating psychiatric symptoms such as psychosis or mania"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Contraindicated"
        },
        {
          "with": "Antihypertensives",
          "risk": "Reduced efficacy of antihypertensives",
          "action": "Monitor BP"
        },
        {
          "with": "Other stimulants",
          "risk": "Increased adverse effects",
          "action": "Avoid combination"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "BP and HR at baseline and periodically",
        "Growth in pediatric patients",
        "Signs of misuse or diversion",
        "Mood and behavior changes"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks; limited human data",
      "lactation": "Excreted in breast milk; monitor infant for irritability or poor weight gain",
      "pediatrics": "Approved for ages 6+",
      "geriatrics": "Limited data; use with caution due to cardiovascular risks"
    },
    {
      "type": "tapering",
      "text": "Gradual dose reduction not typically required, but abrupt discontinuation may cause fatigue or depression."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Take in the morning to avoid insomnia",
        "Do not crush, chew, or split tablets—swallow whole",
        "Effectiveness may wane late in the day in some patients—consider afternoon booster dose of IR formulation"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Concerta Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "American Academy of Pediatrics ADHD Guidelines",
          "url": "https://www.aap.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Methylphenidate ER (Concerta): ADHD Treatment Guide",
    "description": "Concerta is an extended-release formulation of methylphenidate for ADHD, providing up to 12 hours of symptom control."
  }
}
